Technical Analysis for PRAX - Praxis Precision Medicines, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Down |
| Historical PRAX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Fell Below 20 DMA | Bearish | 4.17% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 4.17% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.17% | |
| Outside Day | Range Expansion | 4.17% | |
| 20 DMA Support | Bullish | -0.65% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -0.65% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.65% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 20 DMA Resistance | 1 day ago | |
| Rose Above 20 DMA | 1 day ago | |
| Up 3% | 1 day ago | |
| Up 2% | 1 day ago | |
| 60 Minute Opening Range Breakout | 1 day ago |
Get a Trading Assistant
- Earnings date: ???
Praxis Precision Medicines, Inc. Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cooper Neuroscience Nervous System Disorders Central Nervous System Disorders Precision Medicine Epilepsy Depressive Disorder Major Depressive Disorder Depression Oligonucleotide Huntington's Disease Neuron Spinal Muscular Atrophy Treatment Of Major Depressive Disorder Antisense RNA Receptor Positive Essential Tremor Ionis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 60.95 |
| 52 Week Low | 23.9001 |
| Average Volume | 308,118 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 46.36 |
| 20-Day Moving Average | 56.02 |
| 10-Day Moving Average | 57.53 |
| Average True Range | 3.92 |
| ADX | 31.34 |
| +DI | 17.68 |
| -DI | 16.51 |
| Chandelier Exit (Long, 3 ATRs ) | 49.20 |
| Chandelier Exit (Short, 3 ATRs ) | 55.27 |
| Upper Bollinger Band | 61.81 |
| Lower Bollinger Band | 50.23 |
| Percent B (%b) | 0.54 |
| BandWidth | 20.67 |
| MACD Line | 2.92 |
| MACD Signal Line | 3.75 |
| MACD Histogram | -0.8344 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 62.05 | ||||
| Resistance 3 (R3) | 61.51 | 59.11 | 61.11 | ||
| Resistance 2 (R2) | 59.11 | 57.69 | 59.38 | 60.80 | |
| Resistance 1 (R1) | 57.78 | 56.80 | 58.45 | 58.32 | 60.49 |
| Pivot Point | 55.38 | 55.38 | 55.71 | 55.65 | 55.38 |
| Support 1 (S1) | 54.05 | 53.96 | 54.72 | 54.59 | 52.41 |
| Support 2 (S2) | 51.65 | 53.07 | 51.92 | 52.10 | |
| Support 3 (S3) | 50.32 | 51.65 | 51.79 | ||
| Support 4 (S4) | 50.86 |
